Sanofi

Cyril Daveu

Nicolas Baurin

Han Li

Philip Janiak

Dorothea Kominos

Magali Mathieu

Alla Pritsker

Alexey Rak

Bruno Poirier

Francis Duffieux

Christopher Ryan Morgan

Patrick Grailhe

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

Growing community of inventors

Paris, France

Cyril Daveu